The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Official Title: Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.
Study ID: NCT01121939
Brief Summary: The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and pertuzumab treatment is of great interest. The primary endpoint of this trial will be response rate. Toxicity and progression-free survival will be obtained and evaluated.
Detailed Description: * To determine overall response rate of patients with low grade neuroendocrine cancer when treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®. * To determine the disease control rate (objective response + stable disease), time to treatment progression, progression-free survival, and overall survival in patients with advanced low grade neuroendocrine cancer when treated with bevacizumab, pertuzumab and Sandostatin LAR® treatment. * To define the toxicity and safety of the combination of bevacizumab, pertuzumab and Sandostatin LAR® when used in patients with advanced low grade neuroendocrine cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
Baptist Medical Center East, Louisville, Kentucky, United States
Grand Rapids Oncology Program, Grand Rapids, Michigan, United States
Research Medical Center, Kansas City, Missouri, United States
Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States
Oncology Hematology Care, Inc, Cincinnati, Ohio, United States
Tennessee Oncology Associates, Nashville, Tennessee, United States
Name: Johanna C Bendell, S.B., M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR